We are L-Tryptophan CAS:73-22-3 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
An essential amino acid in human. Not only for protein building, but also important substance as a precursor of niacin, serotonin, melatonin, etc. It is widely used as an ingredient in infusion.
|Specification||White to yellowish white crystals or crystalline powder, odorless, slightly bitter taste|
|STORAGE||Controlled room temperature in tight container|
SPECIFICATION AND PROCEDURE
| State of solution
|Not Less Than 95.0%|
|Ammonium (NH4)||Not More Than 0.020%|
|Chloride (Cl)||Not More Than 0.020%|
|Sulfate (SO4)||Not More Than 0.020%|
|Iron (Fe)||Not More Than 10 ppm|
|Heavy metals (Pb)**||Not More Than 10 ppm|
|Arsenic (As2O3)||Not More Than 1 ppm|
|Related substances||Not More Than 0.5%|
|Loss on drying||Not More Than 0.20%|
|Residue on ignition||Not More Than 0.10%|
|Endotoxin*||Less Than 6.0 EU/g|
|Assay (dry basis)||99.0～101.0%|
· * The endotoxin-certified grade will be supplied on request.
· ** FCC grade (Lead : Not More Than 5 mg/kg) will be supplied on request.
· This product meets requirements of residual solvents listed in the current JP, USP and EP.
Related News: The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment.3-amino-5-bromopiridina CAS:13535-01-8 Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.5-Ethyluracil CAS:4212-49-1 Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.Vinyltriacetoxysilane The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.